Roth Capital affirmed its Focus Pick rating and $33 price target on TG Therapeutics (NASDAQ: TGTX) following the company's Q3 report and update issued earlier Monday.

Analyst Joseph Pantginis commented, We believe that TG is entering an intriguing time as we look toward more mature data updates at ASH and a broadening pivotal program. At ASH, we expect a broad data release to continue to impress and to show a differentiated safety profile, especially with other PI3K inhibitors. With one Phase III ongoing in GENUINE (under SPA), a second starting shortly in UNITY-CLL (under SPA) and a third Phase III for NHL to be announced, TG has fully made the transition to a late stage biotech. The oncology program with TG-1101 and TGR-1202 (TG-1303 for the combination) is running on all cylinders and waiting in the wings are the IRAK4, anti-PDL1 and anti-GITR programs, with IRAK4 expected to enter the clinic in 1H16. The company also now put out a teaser regarding moving its clinical candidates into the autoimmune field and will be launching a trial for multiple sclerosis in the near term and enter Phase III potential in late 2016. Management also indicated that it is already receiving interest from potential partners interested in B-cell targeting.

For an analyst ratings summary and ratings history on TG Therapeutics click here. For more ratings news on TG Therapeutics click here.